Authors: Yamshchikov, G Thompson, L Ross, WG Galavotti, H Aquila, W Deacon, D Caldwell, J Patterson, JW Hunt, DF Slingluff, CL

Citation: G. Yamshchikov et al., Analysis of a natural immune response against tumor antigens in a melanomasurvivor: Lessons applicable to clinical trial evaluations, CLIN CANC R, 7(3), 2001, pp. 909S-916S

Authors: Slingluff, CL Yamshchikov, G Neese, P Galavotti, H Eastham, S Engelhard, VH Kittlesen, D Deacon, D Hibbitts, S Grosh, WW Petroni, G Cohen, R Wiernasz, C Patterson, JW Conway, BP Ross, WG

Citation: Cl. Slingluff et al., Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes, CLIN CANC R, 7(10), 2001, pp. 3012-3024

Authors: Yamshchikov, GV Barnd, DL Eastham, S Galavotti, H Patterson, JW Deacon, DH Teates, D Neese, P Grosh, WW Petroni, G Engelhard, VH Slingluff, GL

Citation: Gv. Yamshchikov et al., Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients, INT J CANC, 92(5), 2001, pp. 703-711